^
Association details:
| Biomarker: | RMST-ALK rearrangement |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Zykadia (ceritinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Identification of a novel RMST-ALK rearrangement in advanced lung adenocarcinoma and durable response to ceritinib: A case report
Published date:
08/01/2022
Excerpt:
...a novel rhabdomyosarcoma 2-associated transcript (RMST)-ALK rearrangement was identified in an 80-year-old Chinese man with advanced lung adenocarcinoma. The patient was prescribed ceritinib and achieved a partial response, which has been sustained for more than 18 months.
DOI:
10.3389/fonc.2022.913838
